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During the course of reversed-phase high-pressure liquid chromatography (RP-HPLC) purification of the 
7B2 peptide originally isolated in our laboratory from human pituitary gland extracts, two novel peptides 
were identified and purified to homogeneity. The complete amino acid sequence of the first one was estab- 
lished in 1985 and recently found to be entirely homologous to positions 420-493 of the just published chro- 
mogranin B sequence. This peptide, denoted GAWK, could originate from chromogranin B following spe- 
cific cleavage at the basic amino acids flanking both termini of GAWK. Moreover, another peptide isolated 
in our laboratory from the same source and denoted CCB has been discovered and its sequence is also part 
of the same chromogranin B molecule. Here again, this peptide, occupying positions 597-653 and located 
at the COOH-terminal region of chromogranin B, could derive from specific processing at basic amino 
acids, Arg-Lys-Lys, present at positions 594-596. In a manner eminiscent of the relationship between pan- 
creastatin and chromogranin A, it is proposed that both GAWK and CCB are produced from chromogran- 
in B after specific processing at basic amino acids. These data are thus in favor of a putative role ofchromo- 
granins as precursors to potentially bioactive peptides. 
Chromogranin; Secretogranin; Prohormone precursor; Peptide processing; GAWK; CCB 
1. INTRODUCTION 
The recent availability of the complete amino 
acid sequence derived from sequencing of cDNA 
of both chromogranin A [1,2] and secretogranin I 
(hereafter eferred to as chromogranin B) [3] has 
stirred considerable interest in the field of neuroen- 
docrinology. Together with chromogranin C, for 
which the primary structure is still unknown, these 
high molecular mass proteins are known to be 
highly acidic and to be extensively posttransla- 
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tionally modified. Furthermore, they have been 
localized in a great number of secretory granules 
derived from endocrine and neuroendocrine ceils 
[4-6]. On the other hand, apart from the reported 
calcium-binding activity of chromogranin A [7], 
their biological role has puzzled and eluded scien- 
tists for a number of years. Due mainly to their low 
p I  and their localization, some possible roles have 
been proposed even though unascertained due to 
lack of purified products. These include involve- 
ment in the packaging and sorting of regulatory 
peptides, in the organization of secretory granule 
contents, as carrier for peptides after secretion and 
as precursors for biologically active p ptides [1-6]. 
Moreover, chromogranin A which contains an 
Arg-Gly-Asp sequence, could per se interact with 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
142 00145793/87/$3.50 © 1987 Federation of European Biochemical Societies 
Volume 224, number 1 FEBS LETTERS November 1987 
cellular membranes and thus act upon target cells 
[1,2]. Finally, we have recently reported that 
chromogranin A could also act as a reversible in- 
hibitor of a putative processing enzyme [8]. 
In 1985, our laboratory reported the isolation, 
immunocytochemical localization and complete se- 
quence of a novel peptide, denoted as GAWK, 
found in human pituitary extracts [9]. We have 
since found that this 74 amino acid peptide is en- 
tirely homologous to positions 420-493 of the just 
reported sequence of chromogranin B [3]. Even 
more interestingly, this peptide is flanked at both 
COOH-  and NH2-termini by pairs of basic amino 
acids in the chromogranin B sequence. Further- 
more, we noticed that GAWK 1-74, itself, is con- 
verted into two smaller fragments, GAWK 1-17 
and 20-74, following cleavage at an Arg-Arg pair 
occupying position 18-19. 
The present report demonstrates that, in addi- 
tion, another peptide from human pituitary ex- 
tracts could be derived from cleavage at a pair of 
basic residues, from the chromogranin B molecule. 
This peptide, hereafter referred to as CCB 
(C_OOH-terminal region of chromogranin B), is 
entirely homologous to positions 597-653 of 
chromogranin B. We also describe preliminary 
results pertaining to tissue, cellular and subcellular 
distribution of GAWK and CCB. 
2. MATERIALS AND METHODS 
2.1. Purification of CCB 
Initial results were obtained using whole human 
pituitary extracts fractionated on a (2.5 x 30 cm) 
Cls semi-preparative HPLC column. The peptides, 
coeluting with the COOH-terminal peptide of pro- 
pressophysin (CPP) [10], were pooled and 
repurified on a Waters/~-Bondapak C~8 (0.78 x 
30 cm) using an aqueous phase containing either 
0.1°70 trifluoroacetic acid (TFA) or 0.13% hep- 
tafluorobutyric acid (HFBA) and a gradient of 
acetonitrile at a flow rate of 2 ml/min. The 
purified fraction was used for amino acid sequence 
screening and the information so obtained allowed 
us to prepare an antiserum. 
A larger preparation of CCB was made starting 
with 2000 frozen pituitaries (1034 g). The extrac- 
tion was carried out using 4585 ml of 0.1 M am- 
monium acetate, pH 6.8, containing 2.5 mM 
EDTA, 0.1/~M pepstatin A and 1 mM PMSF. 
After centrifugation at low speed (8000 rpm) for 
30 min and filtration, the supernatant is adsorbed 
onto Cla-silica which had been previously 
equilibrated in 0.1% TFA containing 5°70 
acetonitrile. After removal of unadsorbed material 
and washing with starting buffer by filtration, the 
adsorbed peptides are extracted in batch-wise man- 
ner using 0.1% TFA containing 45% acetonitrile. 
The eluted fraction after lyophilization is then 
loaded on a /~-Bondapak-C18 column (0.78 x 
30 cm) eluted with a linear gradient from 20% to 
80% acetonitrile containing 0.1% TFA in 120 min 
at a flow rate of 2 ml/min. The major im- 
munoreactive peak was repurified on an Aquapore 
RP-300 (0.7 x 25 cm) column eluted with a linear 
gradient from 30% to 80% 2-propanol containing 
0.1% HFBA in 100min at a flow rate of 
2 ml/min. The immunoreactive material was fur- 
ther purified using an Ultrasphere-ODS (1 x 
25 cm) column eluted with a linear gradient from 
40% to 90% organic phase in 100 rain at a flow 
rate of 2 ml/min: the aqueous phase was made 
with 0.2 M triethylamine phosphate (TEAP), pH 
3.0, while the organic phase was acetonitrile" 
0.175 M TEAP (70:30, v/v). The fractions were 
desalted on an RP-300 Aquapore column using a 
linear gradient from 20% to 60% acetonitrile in 
80 min in the presence of 0.1% TFA at a flow rate 
of 2 ml/min. The immunoreactive p aks were fur- 
ther purified by molecular sieving using a Bio Sil 
TSK-250 column (0.75 x 60 cm) eluted with 0.1 M 
ammonium acetate, pH 6.8, at a flow rate of 
1 ml/min. Each purified fraction was analysed by 
gel electrophoresis using either SDS-urea poly- 
acrylamide or 15% polyacrylamide. 
2.2. Amino acid and sequence analysis 
The HPLC-purif ied peptides were hydrolyzed in 
vacuo using 5.7 N HCI at l l0°C for 24 h. The 
amino acids were separated and quantitated on a 
modified Beckman 120C autoanalyser equipped 
with a Varian DS604 plotter/integrator: detection 
was carried out using post-column inhydrin. 
The amino acid sequence determinations were 
carried out on two automatic sequenators. The 
liquid-phase Beckman 890M and the gas-phase 
Applied Biosystem model 470A sequenators were 
operated as described in [11]. The released 
thiazolinones, after conversion into PTH 
143 
Volume 224, number 1 FEBS LETTERS November 1987 
derivatives, were separated and quantitated by 
HPLC as described [12]. 
2.3. Enzymatic and chemical cleavages 
Carboxypeptidase Y digestion was performed on 
4.8 nmol of the purified fraction dissolved in 60/A 
of 0.1 M ammonium acetate buffer, pH 5.5, to 
which 1.7/zg exopeptidase was added and the in- 
cubation was allowed to proceed for various time 
intervals (1, 5, 10, 15, 30 and 60 min). Amino acid 
analysis was carried out on 10/A acidified (pH 2.2) 
aliquot in the presence of added norleucine acting 
as an internal standard. 
The purified peptide was also cleaved with 
cyanogen bromide (CNBr) in 70°70 formic acid in 
the dark for 24 h. After lyophilizing the reaction 
mixture, the fragments produced were sequenced 
directly without prior separation. 
2.4. Immunological methods 
The information obtained following the first 
NHz-terminal Edman degradation allowed us to 
develop an antiserum against a synthetic fragment 
corresponding to positions 6-21 of the CCB pep- 
tide. However, this synthetic peptide contained a
substitution at position 5 where a Phe residue was 
put instead of a Ser residue as determined by later 
sequencing of CCB. A radioimmunoassay pro- 
cedure using this 125I-labeled synthetic peptide as 
tracer was also developed; the EDso obtained from 
the displacement curve corresponds to 2.2 ng/ml. 
The antibody did not cross-react to any ap- 
preciable xtent with known peptides tested; these 
included fl-endorphin, o~-MSH, human ~-LPH, 
human NHz-terminal of POMC, ACTH and 
human 7B2 (positions 117-128). It also proved 
unable to recognize CCB in species other than 
human such as rat, monkey, porcine and ovine. 
Immunocytochemical localization studies were 
conducted essentially as described in [9]. 
3. RESULTS 
At the time we reported the isolation of GAWK, 
we noticed while purifying 7B2 [13] that numerous 
fractions were contaminated by a peptide contain- 
ing an unusually high amount of acidic residues. 
After purification by HPLC, enough material was 
isolated in order to deduce the amino acid se- 
quence of the first 40 residues (not shown). It was 
thus possible (i) to confirm its acidic character, (ii) 
to confirm its novelty since computer data bank 
search (NBRF) failed to reveal any significant 
homology to known proteins or fragments hereof 
and (iii) to synthesize chemically a segment com- 
prising positions 6-21 for the production of an an- 
tibody. This fragment was chosen in order to 
minimize any cross-reactivity with the NHz-termi- 
nal fragment of human POMC [14] which contains 
in positions 29-35 a sequence similar to the first 
six NH2-terminal amino acids of CCB. 
As can be seen in fig. 1A, the purification of this 
peptide starting from a batch-eluted fraction (see 
section 2) proved especially difficult since the ma- 
jority of the immunoreactive material elutes be- 
tween 40 and 48 min together with a number of 
other peptides. On the other hand, it is worth men- 
tioning that inclusion of an adsorptive step on 
C~8-silica allowed the extraction of material on a
large scale and thus minimized the number of 
passages through separative or semi-preparative 
columns. Following a number of chromatographic 
steps, utilizing various ion-pairing agents or 
organic solvents, it was possible to obtain a suffi- 
ciently pure product (fig.lB) to extend the 
NHz-terminal sequence past the first 40 residues. 
The results from the NHz-terminal Edman 
degradation are shown in fig.2 and allow the iden- 
tification of 57 residues. The characterization of
the cleavage products at the single Met residue oc- 
cupying position 46 confirms that the last iden- 
tifiable residue belonging to the peptide starting at 
residue 47 is a Phe (not shown). The amino acid 
composition (table 1) agrees with the identification 
of the Phe as the COOH-terminal residue and in- 
dicates that the last 4 residues, Ser-Gln-Arg-Gly, 
are missing. The digestion by carboxypeptidase Y 
yields in all cases a complex pattern of released 
amino acids from which Gly and Arg were always 
absent (not shown). Thus, the major form of CCB 
as identified here does appear to be COOH- 
terminal truncated; this, together with the ob- 
served heterogeneity during HPLC purification, 
could be explained by proteolysis occurring after 
the autopsy and prior to storage. It must also be 
said that analysis of the immunoreactive fractions 
isolated by HPLC reveals that this peptide 
migrates abnormally during gel electrophoresis. 
Thus, for example, material analyzed by amino 
acid sequencing migrates routinely as a 15-16 kDa 
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Fig.1. Reverse-phase HPLC purification of the 
polypeptide from whole human pituitary extracts. 
Chromatogram A depicts the HPLC purification of 
immunoreactive CCB previously enriched by C18-batch 
extraction. The immunoreactive fractions (shown as 
histograms) were pooled and repurified (see section 2) to 
yield the fraction (chromatogram B) submitted to amino 
acid sequencing. The dashed lines represent the linear 
gradient of organic phase used in each case. 
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Fig.2. Automatic NH2-terminal degradation of CCB. 
Quantitative yields of PTH-amino acids normalized to a 
PTH-norleucine internal standard are illustrated as a 
function of residue numbers. The slope and intercept 
were obtained by a linear regression analysis on selected 
stable PTH-amino acids giving the repetitive yield 
(94.1%) and initial yield (2.28 nmol), respectively. 
Table 1 
Amino acid composition of CCB 
Amino acid CCB a Chromogranin B b 
(597-657) 
Asx 7.93 (8) 8 
peptide on 1507o polyacrylamide gels and as Thr 2.84(3) 3 
13-14 kDa on SDS-urea gels which is almost twice Ser 3.07 (3) 4 
Glx 15.16 (15) 16 
its expected molecular mass. It is tempting to Pro 2.05 (2) 2 
speculate that such a behavior could at least be ex- Gly 0.41 ( - )  1 
plained by the very high number (28070 of the total Ala 5.76 (6) 6 
residues) of  acidic residues distributed throughout Val 1.98 (2) 2 
the molecule which might prevent he formation of  Met 0.84 (1) 1 
stable peptide-SDS complex. This abnormal Ile 0.97 (1) 1 
migration on gel electrophoresis has already been Leu 5.17 (5) 5 
observed in the case of both chromogranin Tyr 1.06 (1) 1 
molecules [1-3]. Phe 3.13 (3) 3 
The tissue distribution of  CCB reveals that His 1.02 (1) 1 
human pituitary gland and human adrenal are the Lys 4.84 (5) 5 
richest tissues containing 152 and 18 ng/mg of Arg 1.16 (1) 2 
protein, respectively: human testes, liver and Total 57 61 
plasma did not contain any whereas various brain " The computed values represent the average of three 
regions contain different amounts of  immunoreac- analyses. Values in parentheses represent the nearest 
tive material ranging from 0.7 ng/mg to integer 
6.9 ng /mg of protein. Furthermore, no im- b These values are taken from the cDNA sequence [3] 
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munoreactive CCB was detected in the pig anterior 
or neurointermediate pituitary lobes and in ovine 
or rat whole pituitaries. This result could be seen 
as evidence that either CCB is absent in these 
species or, in all likelihood, it is not recognized by 
this antiserum. Similar results were also btained 
while using two antibodies raised against GAWK 
1-17 and GAWK 20-38 which appeared to display 
species selectivity (not shown). Thus, the tissue 
distribution of CCB follows very closely that of the 
GAWK peptide [9]. Displacement curves using 
various amounts of tissue extracts always yielded a 
similar profile to that obtained with the synthetic 
peptide. Moreover, as shown in fig.3, cellular 
localization of GAWK reveals that this peptide is 
Fig.3. Immunocytochemical o ocalization of GAWK 
(A,C) with growth hormone (B) and TSH (D) as 
observed by light microscopy on 3,am serial paraffin 
sections of human adenohypophysis. Cells positively 
labeled are indicated by arrows. Magnification is × 365. 
present, using the antiserum raised against posi- 
tions 20-38, in somatotrophs and in thyrotrophs. 
Indeed, colocalization using antibodies to human 
growth hormone and human TSH can clearly be 
seen: no such colocalization can be seen with an- 
tisera against prolactin, ACTH,  LH and FSH. 
Moreover, GAWK was localized by immunoelec- 
t ron  microscopy in spherical secretory granules 
whose sizes were estimated to be about 
450-500 nm in agreement with those associated 
with somatotrophs. Such studies have not yet been 
conducted on CCB but in view of their similar 
origins and tissue distribution, it is reasonable to 
propose that CCB will also be present in identical 
granules. 
4. DISCUSSION 
The present data clearly demonstrate that two 
peptides, GAWK and CCB, isolated from pituitary 
extracts represent two segments of chromogranin 
B (fig.4). The sequence of GAWK covers positions 
420-493 while CCB corresponds to positions 
597-653. In all likelihood, the full CCB probably 
extends to the last Gly residue which could thus 
yield an amidated peptide. However, according to 
Bradbury and Smyth [15], this should not be the 
case considering the slower kinetics of the amida- 
tion enzyme observed whenever a neutral residue 
occupying the penultimate position is replaced by 
a charged residue for instance, in this case, an Arg 
residue. However, due to the observed 
heterogeneity during the purification and amino 
acid analysis, the presence of a longer form having 
an amidated COOH-terminus, at least in some 
molecules, cannot be excluded. 
Interestingly, other peptides were also reported 
and can now be related to the chromogranin B se- 
quence [16,17]. Indeed, the occurrence in ovine 
adrenal medulla of two peptides, one derived from 
the other by cleavage at an Arg-Arg pair, and 
displaying very high homology to the GAWK pep- 
tide has been reported [16]. Similarly, other ovine 
peptides were isolated and their amino acid se- 
quences [17] can now be localized to positions 
568-593 as shown in fig.4. It is worth mentioning 
that all these peptides, GAWK 1-17 and 20-74, 
OA-24/OA-60, OA-8/OA-21 and CCB, are 
flanked in the chromogranin B sequence by pairs 
of basic amino acids which are well recognized 
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Fig.4. Sequence homology between human GAWK [9], human CCB and various ovine peptides [16,17] with segments 
of human chromogranin B. The alignment of ovine peptide OA-60 sequence with human GAWK was obtained by using 
the program ALIGN from the National Biomedical Research Foundation (Washington, DC). The arrows indicate the 
sites of cleavage necessary to generate he identified peptides whereas asterisks indicate the NHz-termini of other isolated 
fragments. 
sites of proteolytic leavage in prohormones [18]. 
Furthermore, Tatemoto et al. [19] have described 
a novel porcine C-terminally amidated peptide, 
pancreastatin, which inhibits insulin secretion and 
displays a significant sequence homology to posi- 
tions 261-314 of prechromogranin A [20,21]. 
These findings must also be related to numerous 
reports concerning the occurrence of a 21 kDa 
fragment, known as h'-granin, which is cosecreted 
with insulin [22]: this fragment is structurally 
related to the NH2-terminal region of chromo- 
granin A and also appears to be produced after 
cleavage at a pair of basic residues [23]. Based 
upon these data, it appears that, indeed, chromo- 
granin B and chromogranin A could represent 
precursors to smaller peptides whose significance 
remains to be established. 
This report also describes evidence that 
fragments of chromogranin B, namely the GAWK- 
like immunoreactivity, are present in somato- 
trophs and in thyrotrophs. Thus, it is conceivable 
that secretion of GAWK may be stimulated by 
growth-hormone releasing factor (GRF) or in- 
hibited by somatostatin. On the other hand, it is 
known to be released from chromaffin granules by 
common secretagogues such as nicotine and K ÷ 
salts (not shown). However, chromogranin B per 
se was never shown to be present in these cells; in- 
deed, it has been reported in gonadotrophs and in 
corticotrophs but is absent in thyrotrophs, in 
mammotrophs and in somatotrophs [24]. These 
apparently conflicting results could be explained 
by the differential epitope recognizing ability of 
the antibodies used in this and other studies or, 
more attractively, by variable amounts of chromo- 
granin B in these cells. Therefore, chromogranins 
and/or  their fragments can be found in many hor- 
mone producing cells though the processing rates 
of chromogranins appear to be low except for 
chromogranin B in adrenal chromaffin granules 
[25]. Considering the proposed involvement of 
chromogranin A in enzymatic activity regulation 
[8], one can wonder about their role as potential 
competitive substrates or inhibitors and thus as 
potential regulators of the maturation process. 
Clearly more studies are required before any 
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conclusions concerning the biological role of 
chromogranins can be reached. 
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